This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

Concordance data for PD-L1 testing for
non-small cell lung cancer for KEYTRUDA® (pembrolizumab)

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Downloadable infographic demonstrating an overview of testing for in non-small cell lung cancer. It describes the current concordance data between assays by scoring algorithms and cut offs. Please see the Summary of Product Characteristics below for further information regarding KEYTRUDA (pembrolizumab).

to keep updated with the latest educational materials in PD-L1 testing

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website

GB-PDO-01189 | Date of Preparation: November 2020

Concordance data for PD-L1 testing for
non-small cell lung cancer for KEYTRUDA® (pembrolizumab)

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Downloadable infographic demonstrating an overview of testing for in non-small cell lung cancer. It describes the current concordance data between assays by scoring algorithms and cut offs. Please see the Summary of Product Characteristics below for further information regarding KEYTRUDA (pembrolizumab).

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website

GB-PDO-01189 | Date of Preparation: November 2020